What is SBC Medical Group's operating income?

SBC Medical Group's total operating income in 2025 was $67.49 million, based on the following breakdown: Total Gross Profit: $127.28 million Total Operating Expenses: $59.80 million

SBC Medical Group (SBC) Financials

$2.98 +0.01 (+0.34%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$2.97 -0.01 (-0.34%)

As of 07/9/2026 04:10 PM Eastern

Compare

Annual Income Statements for SBC Medical Group

This table shows SBC Medical Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	39	47	51
Consolidated Net Income / (Loss)	39	47	51
Net Income / (Loss) Continuing Operations	39	47	51
Total Pre-Tax Income	74	73	82
Total Operating Income	71	70	67
Total Gross Profit	137	156	127
Total Revenue	194	205	174
Operating Revenue	194	205	174
Total Cost of Revenue	56	49	46
Operating Cost of Revenue	56	49	46
Total Operating Expenses	67	86	60
Selling, General & Admin Expense	66	58	60
Impairment Charge	0.00	15	0.00
Other Special Charges / (Income)	0.00	13	0.00
Total Other Income / (Expense), net	2.92	3.15	15
Interest Expense	0.05	0.03	0.16
Interest & Investment Income	0.09	0.02	0.20
Other Income / (Expense), net	2.88	3.16	15
Income Tax Expense	35	27	31
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.81	0.08	0.06
Basic Earnings per Share	$0.42	$0.48	$0.50
Weighted Average Basic Shares Outstanding	94.19M	96.56M	103.00M
Diluted Earnings per Share	$0.42	$0.48	$0.50
Weighted Average Diluted Shares Outstanding	94.19M	96.56M	103.00M
Weighted Average Basic & Diluted Shares Outstanding	5.22M	103.61M	102.58M

This table shows SBC Medical Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	8.36	30	19	18	2.83	44	22	2.46	13	14	11
Consolidated Net Income / (Loss)	8.06	30	19	19	2.83	44	21	2.44	13	14	11
Net Income / (Loss) Continuing Operations	8.06	30	19	19	2.83	44	21	2.44	13	14	11
Total Pre-Tax Income	21	51	27	27	13	61	31	14	19	19	19
Total Operating Income	20	51	24	27	14	57	24	15	16	13	18
Total Gross Profit	33	104	40	39	43	113	38	30	31	29	30
Total Revenue	47	146	55	53	53	152	47	43	43	40	43
Operating Revenue	47	-	55	53	53	-	47	43	43	40	43
Total Cost of Revenue	14	42	15	14	9.85	39	9.60	13	13	11	13
Operating Cost of Revenue	14	-	15	14	9.85	-	9.60	13	13	11	13
Total Operating Expenses	13	52	15	12	29	55	14	15	15	16	13
Selling, General & Admin Expense	13	-	15	12	17	-	14	15	15	16	13
Total Other Income / (Expense), net	1.05	-0.23	2.74	-0.20	-0.73	3.39	7.25	-1.01	2.63	5.72	1.14
Interest Expense	0.00	-	0.00	0.01	0.01	-	0.01	0.05	0.05	0.06	0.11
Interest & Investment Income	0.01	-2.02	0.02	0.01	0.01	-0.48	0.06	0.02	0.12	-0.00	0.12
Other Income / (Expense), net	1.04	-	2.73	-0.21	-0.73	-	7.20	-0.99	2.55	5.77	1.13
Income Tax Expense	13	22	8.45	8.53	10	16	9.96	11	5.67	4.29	7.53
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.30	-	-0.01	0.07	0.00	-	-0.01	-0.02	0.01	0.08	0.02
Basic Earnings per Share	$0.09	$0.29	$0.20	$0.20	$0.03	$0.57	$0.21	$0.02	$0.12	$0.15	$0.11
Weighted Average Basic Shares Outstanding	94.19M	94.19M	94.19M	94.19M	95.10M	96.56M	103.28M	103.51M	102.64M	103.00M	102.58M
Diluted Earnings per Share	$0.09	$0.29	$0.20	$0.20	$0.03	$0.57	$0.21	$0.02	$0.12	$0.15	$0.11
Weighted Average Diluted Shares Outstanding	94.19M	94.19M	94.19M	94.19M	95.10M	96.56M	103.28M	103.51M	102.64M	103.00M	102.58M
Weighted Average Basic & Diluted Shares Outstanding	5.49M	5.22M	5.22M	5.22M	103.02M	103.61M	103.61M	103.88M	102.58M	102.58M	102.85M

This table details how cash moves in and out of SBC Medical Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	51	22	39
Net Cash From Operating Activities	51	21	25
Net Cash From Continuing Operating Activities	51	21	25
Net Income / (Loss) Continuing Operations	39	47	51
Consolidated Net Income / (Loss)	39	47	51
Depreciation Expense	12	3.80	2.68
Non-Cash Adjustments To Reconcile Net Income	-0.16	-1.45	-22
Changes in Operating Assets and Liabilities, net	0.03	-28	-7.27
Net Cash From Investing Activities	1.79	-10	-21
Net Cash From Continuing Investing Activities	1.79	-10	-21
Purchase of Property, Plant & Equipment	-8.54	-2.56	-1.40
Acquisitions	-1.68	-0.83	0.00
Purchase of Investments	-4.42	-0.95	-21
Sale of Property, Plant & Equipment	8.05	0.00	7.48
Other Investing Activities, net	4.26	-5.75	-6.00
Net Cash From Financing Activities	6.14	23	38
Net Cash From Continuing Financing Activities	6.14	23	38
Repayment of Debt	-16	-0.86	-1.83
Repurchase of Common Equity	-	0.00	-5.00
Issuance of Debt	12	17	0.02
Other Financing Activities, net	10	6.63	45
Effect of Exchange Rate Changes	-7.31	-11	-3.26
Cash Interest Paid	0.05	0.03	0.16
Cash Income Taxes Paid	18	30	37

This table details how cash moves in and out of SBC Medical Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	25	26	-6.84	-0.27	33	-12	7.01	21	-25	36	3.53
Net Cash From Operating Activities	24	28	3.68	-0.41	29	-7.30	1.93	-8.34	-21	52	9.23
Net Cash From Continuing Operating Activities	24	28	3.68	-0.41	29	-7.30	1.93	-8.34	-21	52	9.23
Net Income / (Loss) Continuing Operations	24	14	19	-0.31	41	6.55	21	2.44	13	14	11
Consolidated Net Income / (Loss)	24	14	19	-0.31	41	6.55	21	2.44	13	14	11
Depreciation Expense	-	2.56	1.02	-	-	0.93	0.63	0.64	0.75	0.67	0.67
Non-Cash Adjustments To Reconcile Net Income	0.21	1.73	-2.64	-0.23	0.54	13	-8.06	-2.78	-7.93	-3.02	1.50
Changes in Operating Assets and Liabilities, net	-9.35	9.40	-13	0.13	-15	-28	-12	-8.64	-27	40	-4.27
Net Cash From Investing Activities	-92	-6.87	-3.39	0.13	-8.81	-4.55	-0.98	16	-12	-24	-0.53
Net Cash From Continuing Investing Activities	-92	-6.87	-3.39	0.13	-8.81	-4.55	-0.98	16	-12	-24	-0.53
Purchase of Property, Plant & Equipment	-	-6.24	-0.70	-	-	-0.59	-0.25	-0.31	-0.04	-0.80	-0.12
Purchase of Investments	-	-1.29	-0.37	-	-	-0.01	-0.64	-0.02	-0.00	-20	0.00
Sale of Property, Plant & Equipment	-	-	0.00	-	-	-0.00	0.32	1.40	1.03	4.72	0.00
Other Investing Activities, net	-98	1.37	-1.51	0.13	-5.08	-3.93	-0.41	15	-13	-7.74	-0.40
Net Cash From Financing Activities	105	-0.13	-0.04	-	13	11	-0.28	7.18	12	20	-1.84
Net Cash From Continuing Financing Activities	105	-0.13	-0.04	-	13	11	-0.28	7.18	12	20	-1.84
Repayment of Debt	-	-0.13	-0.04	-	-	-0.70	-0.30	-0.08	14	-16	-1.84
Issuance of Debt	11	-	0.00	-	10	12	0.02	-	-	-	0.00
Other Financing Activities, net	-	-	-	-	-	-	0.00	-	-	35	0.00
Effect of Exchange Rate Changes	-	4.67	-7.09	-	-	-12	6.34	5.47	-3.84	-11	-3.33
Cash Interest Paid	-	0.01	0.00	-	-	0.01	0.01	0.05	0.05	0.06	0.11
Cash Income Taxes Paid	12	5.23	16	-	31	-1.09	21	-0.94	18	-0.37	8.85

This table presents SBC Medical Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	120	259	266	380
Total Current Assets	0.72	166	184	231
Cash & Equivalents	0.49	103	125	164
Short-Term Investments	-	-	0.00	0.32
Note & Lease Receivable	-	15	16	22
Accounts Receivable	-	69	59	57
Inventories, net	-	3.09	1.49	2.79
Prepaid Expenses	0.24	10	11	12
Current Deferred & Refundable Income Taxes	-	-	0.00	1.18
Plant, Property, & Equipment, net	0.00	14	8.77	7.54
Total Noncurrent Assets	119	79	91	142
Long-Term Investments	-	21	39	39
Noncurrent Note & Lease Receivables	-	9.86	13	19
Goodwill	-	3.59	4.61	15
Intangible Assets	-	20	1.59	48
Noncurrent Deferred & Refundable Income Taxes	-	0.00	9.80	4.01
Other Noncurrent Operating Assets	119	25	23	16
Total Liabilities & Shareholders' Equity	120	259	266	380
Total Liabilities	4.59	115	71	117
Total Current Liabilities	0.57	92	61	61
Short-Term Debt	0.00	3.53	0.12	9.10
Accounts Payable	0.08	27	15	18
Accrued Expenses	0.08	21	8.10	12
Current Deferred Revenue	-	25	13	6.77
Current Deferred & Payable Income Tax Liabilities	0.25	8.78	19	8.82
Other Current Liabilities	0.16	7.47	16	9.94
Total Noncurrent Liabilities	4.03	23	18	56
Long-Term Debt	-	13	6.51	34
Noncurrent Deferred & Payable Income Tax Liabilities	-	6.01	0.93	16
Other Noncurrent Operating Liabilities	-	3.52	11	5.91
Commitments & Contingencies	0.00	-	0.00	0.00
Total Equity & Noncontrolling Interests	-3.36	144	195	263
Total Preferred & Common Equity	-3.36	142	195	248
Preferred Stock	0.00	0.00	0.00	0.00
Total Common Equity	-3.36	142	195	248
Common Stock	0.00	37	63	73
Retained Earnings	-3.36	143	189	240
Treasury Stock	-	0.00	-2.70	-7.75
Accumulated Other Comprehensive Income / (Loss)	-	-38	-54	-57
Noncontrolling Interest	-	1.65	-0.09	15

This table presents SBC Medical Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	119	121	22	21	20	20	296	285	315	321	388
Total Current Assets	0.84	0.47	1.15	0.74	1.77	1.44	202	215	241	227	239
Cash & Equivalents	0.58	-	0.97	0.57	1.66	1.38	137	132	153	127	167
Short-Term Investments	-	-	-	-	-	-	-	-	-	-	0.31
Note & Lease Receivable	-	-	-	-	-	-	-	16	-	-	20
Accounts Receivable	-	-	-	-	-	-	58	63	105	120	71
Inventories, net	-	-	-	-	-	-	1.99	1.69	1.71	1.68	2.32
Prepaid Expenses	0.26	0.25	0.18	0.16	0.11	0.06	8.37	33	14	15	11
Current Deferred & Refundable Income Taxes	-	-	-	0.01	-	-	-	-	-	-	1.17
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	13	8.52	8.06	7.00	7.29
Total Noncurrent Assets	118	120	20	21	18	18	41	80	22	42	142
Long-Term Investments	-	-	-	-	-	-	-	41	-	-	39
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	-	16	0.52	0.48	16
Goodwill	-	-	-	-	-	-	3.55	4.78	5.01	4.92	15
Intangible Assets	-	-	-	-	-	-	16	1.54	1.58	23	47
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	0.62	2.51	2.34	0.61	4.98
Other Noncurrent Operating Assets	118	120	20	21	18	18	21	14	12	12	19
Total Liabilities & Shareholders' Equity	119	121	22	21	20	20	296	285	315	321	388
Total Liabilities	4.29	4.86	6.51	6.47	8.43	8.51	91	58	71	73	118
Total Current Liabilities	0.26	0.84	2.49	2.45	4.40	4.48	72	48	61	45	63
Short-Term Debt	-	-	1.00	1.00	2.70	2.70	10	1.49	3.34	4.68	8.99
Accounts Payable	0.08	0.08	0.08	0.03	0.06	0.08	15	20	20	20	20
Accrued Expenses	-	0.20	0.35	0.35	0.51	0.66	12	8.56	6.23	4.56	12
Current Deferred Revenue	-	-	-	-	-	-	20	11	11	7.99	5.23
Current Deferred & Payable Income Tax Liabilities	0.06	0.51	0.01	0.00	0.06	0.02	8.00	1.62	14	0.77	8.45
Other Current Liabilities	0.13	0.05	0.04	0.06	0.04	-	7.59	7.11	16	19	11
Total Noncurrent Liabilities	4.03	4.03	4.03	4.03	4.03	4.03	19	9.82	9.97	29	55
Long-Term Debt	-	-	-	-	-	-	12	6.81	7.03	18	31
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	3.52	0.35	-	-	16
Other Noncurrent Operating Liabilities	-	-	-	-	-	-	2.68	2.66	16	18	7.40
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	0.00
Total Equity & Noncontrolling Interests	-3.16	-3.73	-5.21	-5.57	9.02	8.83	206	226	245	248	270
Total Preferred & Common Equity	-3.16	-3.73	-5.21	-5.57	9.02	8.83	205	226	245	248	255
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-3.16	-3.73	-5.21	-5.57	9.02	8.83	205	226	245	248	255
Common Stock	0.00	0.00	0.00	0.00	15	15	61	63	72	72	73
Retained Earnings	-3.16	-3.73	-5.21	-5.57	-6.29	-6.60	183	211	213	226	252
Treasury Stock	-	-	-	-	-	-	-2.70	-2.70	-5.12	-7.75	-7.75
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	-	-36	-44	-36	-43	-62
Noncontrolling Interest	-	-	-	-	-	-	0.54	-0.12	0.06	0.07	15

This table displays calculated financial ratios and metrics derived from SBC Medical Group's official financial filings.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	102,576,943.00
DEI Adjusted Shares Outstanding	-	-	102,576,943.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	0.50
Growth Metrics	-	-	-
Revenue Growth	0.00%	6.13%	-15.48%
EBITDA Growth	0.00%	-9.93%	9.64%
EBIT Growth	0.00%	-0.10%	11.66%
NOPAT Growth	0.00%	20.67%	-6.06%
Net Income Growth	0.00%	21.08%	9.33%
EPS Growth	0.00%	14.29%	4.17%
Operating Cash Flow Growth	0.00%	-59.38%	19.85%
Free Cash Flow Firm Growth	0.00%	0.00%	-137.41%
Invested Capital Growth	0.00%	19.32%	90.02%
Revenue Q/Q Growth	0.00%	3,437.87%	-2.72%
EBITDA Q/Q Growth	0.00%	1,053.16%	16.95%
EBIT Q/Q Growth	0.00%	1,006.29%	18.04%
NOPAT Q/Q Growth	0.00%	887.53%	13.57%
Net Income Q/Q Growth	0.00%	841.76%	17.85%
EPS Q/Q Growth	0.00%	318.18%	25.00%
Operating Cash Flow Q/Q Growth	0.00%	586.25%	171.30%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	48.55%
Invested Capital Q/Q Growth	0.00%	55.18%	0.47%
Profitability Metrics	-	-	-
Gross Margin	70.94%	75.97%	73.32%
EBITDA Margin	44.32%	37.61%	48.80%
Operating Margin	36.51%	34.23%	38.87%
EBIT Margin	38.00%	35.76%	47.25%
Profit (Net Income) Margin	19.92%	22.73%	29.40%
Tax Burden Percent	52.41%	63.56%	62.20%
Interest Burden Percent	100.06%	99.99%	100.05%
Effective Tax Rate	47.59%	36.44%	37.80%
Return on Invested Capital (ROIC)	52.65%	57.93%	43.39%
ROIC Less NNEP Spread (ROIC-NNEP)	50.56%	55.76%	36.54%
Return on Net Nonoperating Assets (RNNOA)	-25.83%	-30.38%	-21.12%
Return on Equity (ROE)	26.81%	27.56%	22.27%
Cash Return on Invested Capital (CROIC)	0.00%	40.32%	-18.68%
Operating Return on Assets (OROA)	38.83%	27.99%	25.37%
Return on Assets (ROA)	20.36%	17.79%	15.79%
Return on Common Equity (ROCE)	14.36%	27.43%	21.55%
Return on Equity Simple (ROE_SIMPLE)	27.13%	23.93%	0.00%
Net Operating Profit after Tax (NOPAT)	37	45	42
NOPAT Margin	19.13%	21.75%	24.18%
Net Nonoperating Expense Percent (NNEP)	2.08%	2.17%	6.85%
Return On Investment Capital (ROIC_SIMPLE)	23.09%	22.16%	13.71%
Cost of Revenue to Revenue	29.06%	24.03%	26.68%
SG&A Expenses to Revenue	34.22%	28.07%	34.44%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	34.43%	41.74%	34.44%
Earnings before Interest and Taxes (EBIT)	74	73	82
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	86	77	85
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.42	2.94	1.78
Price to Tangible Book Value (P/TBV)	0.50	3.03	2.39
Price to Revenue (P/Rev)	0.31	2.79	2.55
Price to Earnings (P/E)	1.50	12.29	8.67
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	66.59%	8.14%	11.53%
Enterprise Value to Invested Capital (EV/IC)	0.00	5.16	2.34
Enterprise Value to Revenue (EV/Rev)	0.00	2.11	1.71
Enterprise Value to EBITDA (EV/EBITDA)	0.00	5.61	3.50
Enterprise Value to EBIT (EV/EBIT)	0.00	5.90	3.61
Enterprise Value to NOPAT (EV/NOPAT)	0.00	9.70	7.06
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	21.06	12.02
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	13.94	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.12	0.03	0.16
Long-Term Debt to Equity	0.09	0.03	0.13
Financial Leverage	-0.51	-0.54	-0.58
Leverage Ratio	1.46	1.55	1.41
Compound Leverage Factor	1.46	1.55	1.41
Debt to Total Capital	10.31%	3.29%	13.99%
Short-Term Debt to Total Capital	2.20%	0.06%	2.97%
Long-Term Debt to Total Capital	8.11%	3.23%	11.02%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	1.03%	-0.04%	4.91%
Common Equity to Total Capital	88.66%	96.75%	81.10%
Debt to EBITDA	0.19	0.09	0.51
Net Debt to EBITDA	-1.25	-1.80	-1.90
Long-Term Debt to EBITDA	0.15	0.08	0.40
Debt to NOPAT	0.45	0.15	1.02
Net Debt to NOPAT	-2.89	-3.12	-3.83
Long-Term Debt to NOPAT	0.35	0.15	0.80
Altman Z-Score	3.11	8.07	4.85
Noncontrolling Interest Sharing Ratio	46.44%	0.46%	3.26%
Liquidity Ratios	-	-	-
Current Ratio	1.79	3.01	3.78
Quick Ratio	2.02	3.28	3.98
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	31	-18
Operating Cash Flow to CapEx	10,188.18%	802.57%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	1,098.93	-112.56
Operating Cash Flow to Interest Expense	1,118.75	727.31	153.62
Operating Cash Flow Less CapEx to Interest Expense	1,107.77	636.69	191.47
Efficiency Ratios	-	-	-
Asset Turnover	1.02	0.78	0.54
Accounts Receivable Turnover	0.00	3.21	2.98
Inventory Turnover	0.00	21.53	21.61
Fixed Asset Turnover	0.00	18.38	21.29
Accounts Payable Turnover	4.23	2.37	2.77
Days Sales Outstanding (DSO)	0.00	113.63	122.49
Days Inventory Outstanding (DIO)	0.00	16.95	16.89
Days Payable Outstanding (DPO)	86.36	154.26	131.92
Cash Conversion Cycle (CCC)	-86.36	-23.67	7.46
Capital & Investment Metrics	-	-	-
Invested Capital	70	84	127
Invested Capital Turnover	2.75	2.66	1.79
Increase / (Decrease) in Invested Capital	0.00	14	60
Enterprise Value (EV)	-46	433	296
Market Capitalization	59	573	442
Book Value per Share	$25.90	$1.89	$2.42
Tangible Book Value per Share	$21.65	$1.83	$1.80
Total Capital	160	202	306
Total Debt	17	6.63	43
Total Long-Term Debt	13	6.51	34
Net Debt	-107	-139	-161
Capital Expenditures (CapEx)	0.50	2.56	-6.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-26	-1.66	15
Debt-free Net Working Capital (DFNWC)	77	123	179
Net Working Capital (NWC)	73	123	170
Net Nonoperating Expense (NNE)	-1.53	-2.00	-9.07
Net Nonoperating Obligations (NNO)	-73	-111	-137
Total Depreciation and Amortization (D&A)	12	3.80	2.68
Debt-free, Cash-free Net Working Capital to Revenue	-13.46%	-0.81%	8.70%
Debt-free Net Working Capital to Revenue	39.77%	60.06%	103.22%
Net Working Capital to Revenue	37.95%	60.00%	97.98%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.48	$0.50
Adjusted Weighted Average Basic Shares Outstanding	8.85M	96.56M	103.00M
Adjusted Diluted Earnings per Share	$0.00	$0.48	$0.50
Adjusted Weighted Average Diluted Shares Outstanding	8.91M	96.56M	103.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.22M	103.61M	102.58M
Normalized Net Operating Profit after Tax (NOPAT)	37	63	42
Normalized NOPAT Margin	19.13%	30.44%	24.18%
Pre Tax Income Margin	38.02%	35.76%	47.27%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	1,623.64	2,595.91	510.81
NOPAT to Interest Expense	817.60	1,579.02	261.40
EBIT Less CapEx to Interest Expense	1,612.66	2,505.28	548.66
NOPAT Less CapEx to Interest Expense	806.62	1,488.40	299.25
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	9.80%

This table displays calculated financial ratios and metrics derived from SBC Medical Group's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	103,611,251.00	103,611,251.00	103,881,251.00	102,576,943.00	102,576,943.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	103,611,251.00	103,611,251.00	103,881,251.00	102,576,943.00	102,576,943.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	0.21	0.02	0.12	0.14	0.11
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	12.28%	4.15%	-13.65%	-18.35%	-18.33%	-10.93%	-9.02%
EBITDA Growth	7,037.60%	0.00%	-29.92%	-5.99%	-37.78%	8.05%	13.56%	-49.12%	35.81%	174.86%	-39.06%
EBIT Growth	7,037.60%	0.00%	-29.92%	-5.99%	-37.78%	11.61%	15.50%	-49.90%	40.67%	205.85%	-39.97%
NOPAT Growth	10,331.95%	0.00%	-29.89%	-37.05%	-60.93%	40.76%	-1.91%	-85.97%	268.12%	93.84%	-35.63%
Net Income Growth	70,664.77%	0.00%	-147.70%	-256.65%	-64.82%	49.72%	14.62%	-86.85%	352.76%	118.08%	-47.29%
EPS Growth	0.00%	0.00%	0.00%	-400.00%	-66.67%	96.55%	5.00%	-90.00%	300.00%	200.00%	-47.62%
Operating Cash Flow Growth	0.00%	0.00%	-23.78%	55.73%	19.58%	-126.16%	-47.62%	-143.45%	-516.73%	811.51%	378.68%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	115.93%	-133.52%	0.00%	-167.10%	-396.01%	-71.14%	-674.99%	82.03%
Invested Capital Growth	-86.51%	0.00%	-89.32%	-18.37%	251.13%	19.32%	786.30%	536.72%	133.29%	90.02%	22.95%
Revenue Q/Q Growth	0.00%	209.37%	0.00%	0.00%	0.00%	186.96%	6.55%	-8.39%	-0.01%	-8.73%	8.83%
EBITDA Q/Q Growth	4,549.72%	156.63%	14.12%	0.58%	2,712.08%	345.67%	356.23%	-55.66%	35.05%	0.60%	1.16%
EBIT Q/Q Growth	4,549.72%	144.49%	14.12%	0.58%	2,712.08%	338.56%	415.72%	-56.80%	35.88%	1.02%	1.22%
NOPAT Q/Q Growth	3,088.18%	289.49%	14.12%	0.58%	951.82%	1,303.31%	224.40%	-84.14%	319.92%	-10.27%	7.73%
Net Income Q/Q Growth	3,994.70%	268.50%	20.03%	-5.37%	1,019.49%	1,468.42%	228.23%	-88.65%	425.99%	11.27%	-20.66%
EPS Q/Q Growth	125.00%	222.22%	0.00%	0.00%	125.00%	1,800.00%	320.00%	-90.48%	500.00%	25.00%	-26.67%
Operating Cash Flow Q/Q Growth	2,712.84%	15.98%	-16.80%	16.34%	7,157.57%	-125.38%	126.41%	-532.42%	-150.42%	348.82%	-82.23%
Free Cash Flow Firm Q/Q Growth	799.52%	-100.00%	0.00%	-97.65%	-1,572.24%	179.56%	-1,024.73%	21.22%	3.91%	17.86%	71.09%
Invested Capital Q/Q Growth	1.96%	356.67%	-19.33%	-0.27%	338.59%	55.18%	64.27%	-28.35%	60.70%	0.47%	6.29%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	70.85%	71.01%	0.00%	0.00%	81.45%	74.11%	79.73%	69.21%	70.61%	73.11%	70.47%
EBITDA Margin	44.55%	36.96%	0.00%	0.00%	24.69%	38.34%	67.68%	32.76%	44.24%	48.77%	45.33%
Operating Margin	42.35%	35.21%	0.00%	0.00%	26.06%	37.73%	51.14%	33.57%	36.63%	32.47%	41.15%
EBIT Margin	44.55%	35.21%	0.00%	0.00%	24.69%	37.73%	66.35%	31.29%	42.52%	47.07%	43.78%
Profit (Net Income) Margin	17.04%	20.30%	0.00%	0.00%	5.34%	29.18%	45.41%	5.63%	29.60%	36.09%	26.31%
Tax Burden Percent	38.24%	57.91%	118.28%	115.13%	21.62%	73.04%	68.33%	18.02%	69.34%	76.91%	60.08%
Interest Burden Percent	100.03%	99.56%	49.01%	53.37%	100.02%	105.89%	100.16%	99.80%	100.39%	99.70%	100.03%
Effective Tax Rate	61.76%	42.09%	0.00%	0.00%	78.38%	26.96%	31.67%	81.98%	30.66%	23.09%	39.92%
Return on Invested Capital (ROIC)	0.00%	56.11%	0.00%	0.00%	0.94%	73.40%	113.43%	25.06%	50.30%	44.82%	34.27%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	56.29%	0.00%	0.00%	1.15%	70.71%	104.87%	25.28%	48.96%	41.50%	33.73%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-28.76%	0.00%	0.00%	-0.79%	-38.52%	-51.05%	-16.30%	-29.51%	-23.98%	-17.14%
Return on Equity (ROE)	0.00%	27.35%	-0.89%	-8.21%	0.15%	34.88%	62.38%	8.76%	20.79%	20.84%	17.13%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	40.32%	-86.37%	-80.19%	-38.98%	-18.68%	8.80%
Operating Return on Assets (OROA)	0.00%	35.98%	0.00%	0.00%	0.90%	29.53%	86.30%	35.17%	24.57%	25.28%	22.04%
Return on Assets (ROA)	0.00%	20.75%	0.00%	0.00%	0.20%	22.84%	59.06%	6.33%	17.10%	19.38%	13.25%
Return on Common Equity (ROCE)	0.00%	14.65%	-0.04%	-1.14%	0.14%	34.72%	61.80%	8.68%	20.76%	20.16%	16.62%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	-6.28%	-12.13%	-3.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	7.66	30	-0.35	-0.35	2.99	42	17	2.62	11	9.88	11
NOPAT Margin	16.20%	20.39%	0.00%	0.00%	5.64%	27.56%	34.94%	6.05%	25.40%	24.98%	24.72%
Net Nonoperating Expense Percent (NNEP)	518.88%	-0.18%	-14.76%	-6.41%	-0.21%	2.68%	8.56%	-0.22%	1.33%	3.32%	0.54%
Return On Investment Capital (ROIC_SIMPLE)	-	18.60%	-	-	-	20.82%	7.05%	1.03%	4.07%	3.23%	3.43%
Cost of Revenue to Revenue	29.15%	28.99%	0.00%	0.00%	18.55%	25.89%	20.27%	30.79%	29.39%	26.89%	29.53%
SG&A Expenses to Revenue	28.44%	0.00%	0.00%	0.00%	31.27%	0.00%	28.59%	35.65%	33.98%	40.64%	29.32%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	28.50%	35.80%	0.00%	0.00%	55.39%	36.38%	28.59%	35.65%	33.98%	40.64%	29.32%
Earnings before Interest and Taxes (EBIT)	21	51	-0.50	-0.50	13	57	31	14	18	19	19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	21	54	-0.50	-0.50	13	58	32	14	19	19	20
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.42	7.35	7.72	0.20	2.94	1.46	1.97	1.82	1.78	1.68
Price to Tangible Book Value (P/TBV)	0.00	0.50	7.35	7.72	0.22	3.03	1.50	2.02	2.05	2.39	2.22
Price to Revenue (P/Rev)	0.00	0.31	0.00	0.00	7.16	2.79	1.67	2.55	2.53	2.55	2.53
Price to Earnings (P/E)	0.00	1.50	0.00	0.00	0.00	12.29	6.70	14.42	10.41	8.67	10.51
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	66.59%	0.00%	0.00%	0.00%	8.14%	14.93%	6.93%	9.61%	11.53%	9.51%
Enterprise Value to Invested Capital (EV/IC)	5.17	0.00	5.63	5.81	0.00	5.16	1.51	4.31	2.74	2.34	2.06
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	2.11	0.84	1.80	1.94	1.71	1.64
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	5.61	2.04	5.02	4.78	3.50	3.84
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	5.90	2.13	5.27	4.98	3.61	4.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	9.70	3.72	11.37	9.37	7.06	7.73
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	21.06	8.79	0.00	0.00	12.02	8.68
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	13.94	0.00	0.00	0.00	0.00	25.82
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.07	0.12	0.24	0.25	0.11	0.03	0.04	0.04	0.09	0.16	0.15
Long-Term Debt to Equity	0.00	0.09	0.00	0.00	0.06	0.03	0.03	0.03	0.07	0.13	0.12
Financial Leverage	0.00	-0.51	0.01	0.05	-0.68	-0.54	-0.49	-0.64	-0.60	-0.58	-0.51
Leverage Ratio	1.08	1.46	1.10	1.58	1.44	1.55	1.28	1.31	1.36	1.41	1.35
Compound Leverage Factor	1.08	1.45	0.54	0.84	1.44	1.64	1.28	1.31	1.37	1.41	1.35
Debt to Total Capital	6.26%	10.31%	19.25%	19.68%	9.94%	3.29%	3.54%	4.07%	8.40%	13.99%	13.01%
Short-Term Debt to Total Capital	6.26%	2.20%	19.25%	19.68%	4.53%	0.06%	0.64%	1.31%	1.73%	2.97%	2.89%
Long-Term Debt to Total Capital	0.00%	8.11%	0.00%	0.00%	5.41%	3.23%	2.90%	2.76%	6.68%	11.02%	10.12%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	128.60%	1.03%	16.45%	15.93%	0.24%	-0.04%	-0.05%	0.02%	0.03%	4.91%	4.84%
Common Equity to Total Capital	-34.86%	88.66%	64.30%	64.38%	89.82%	96.75%	96.52%	95.91%	91.57%	81.10%	82.15%
Debt to EBITDA	0.00	0.19	-1.43	-1.41	-2.80	0.09	0.10	0.15	0.31	0.51	0.56
Net Debt to EBITDA	0.00	-1.25	-0.55	-0.69	14.15	-1.80	-2.03	-2.11	-1.45	-1.90	-2.30
Long-Term Debt to EBITDA	0.00	0.15	0.00	0.00	-1.52	0.08	0.08	0.10	0.25	0.40	0.44
Debt to NOPAT	0.00	0.45	-2.04	-2.01	-4.00	0.15	0.19	0.35	0.62	1.02	1.13
Net Debt to NOPAT	0.00	-2.89	-0.79	-0.98	20.22	-3.12	-3.70	-4.78	-2.83	-3.83	-4.63
Long-Term Debt to NOPAT	0.00	0.35	0.00	0.00	-2.18	0.15	0.15	0.24	0.49	0.80	0.88
Altman Z-Score	0.00	2.83	4.03	4.06	1.83	7.87	6.20	6.46	6.10	4.30	4.24
Noncontrolling Interest Sharing Ratio	0.00%	46.44%	95.85%	86.11%	9.56%	0.46%	0.92%	0.88%	0.13%	3.26%	3.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.30	1.79	0.40	0.32	2.79	3.01	4.44	3.98	5.10	3.78	3.82
Quick Ratio	0.23	2.02	0.38	0.31	2.69	3.28	4.35	4.25	5.54	3.98	4.13
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	106	0.00	103	2.42	-36	28	-81	-64	-61	-50	-15
Operating Cash Flow to CapEx	0.00%	447.07%	0.00%	0.00%	0.00%	-1,232.98%	0.00%	0.00%	0.00%	0.00%	7,385.85%
Free Cash Flow to Firm to Interest Expense	26,762.21	0.00	0.00	0.00	-6,529.44	0.00	-12,999.00	-1,280.17	-1,255.86	-894.44	-126.32
Operating Cash Flow to Interest Expense	6,050.52	0.00	0.00	0.00	5,265.55	0.00	310.72	-167.97	-429.41	926.44	80.41
Operating Cash Flow Less CapEx to Interest Expense	6,050.52	0.00	0.00	0.00	5,265.55	0.00	321.95	-145.85	-409.16	996.42	79.32
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	1.02	0.00	0.00	0.04	0.78	1.30	1.12	0.58	0.54	0.50
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	3.21	0.00	0.00	2.01	2.98	2.54
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	21.53	0.00	0.00	25.24	21.61	24.61
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	18.38	0.00	0.00	17.68	21.29	21.42
Accounts Payable Turnover	0.00	4.23	2.42	2.09	0.00	2.37	4.32	4.42	2.64	2.77	2.45
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	113.63	0.00	0.00	181.41	122.49	143.66
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	16.95	0.00	0.00	14.46	16.89	14.83
Days Payable Outstanding (DPO)	0.00	86.36	150.64	174.54	0.00	154.26	84.40	82.59	138.06	131.92	148.98
Cash Conversion Cycle (CCC)	0.00	-86.36	0.00	0.00	0.00	-23.67	-84.40	-82.59	57.81	7.46	9.51
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	15	70	12	12	54	84	110	79	126	127	135
Invested Capital Turnover	0.00	2.75	0.00	0.00	0.17	2.66	3.25	4.14	1.98	1.79	1.39
Increase / (Decrease) in Invested Capital	-99	0.00	-103	-2.78	39	14	97	66	72	60	25
Enterprise Value (EV)	80	-46	70	72	-73	433	166	338	346	296	278
Market Capitalization	59	59	66	68	42	573	331	481	451	442	429
Book Value per Share	($1.01)	$25.90	$1.73	$1.69	$2.16	$1.89	$2.19	$2.36	$2.39	$2.42	$2.49
Tangible Book Value per Share	($1.01)	$21.65	$1.73	$1.69	$1.95	$1.83	$2.12	$2.30	$2.12	$1.80	$1.88
Total Capital	16	160	14	14	228	202	235	255	271	306	311
Total Debt	1.00	17	2.70	2.70	23	6.63	8.30	10	23	43	40
Total Long-Term Debt	0.00	13	0.00	0.00	12	6.51	6.81	7.03	18	34	31
Net Debt	0.43	-107	1.04	1.32	-115	-139	-165	-142	-105	-161	-166
Capital Expenditures (CapEx)	0.00	6.24	0.00	0.00	0.00	0.59	-0.07	-1.10	-0.98	-3.93	0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.28	-26	-1.59	-1.73	2.63	-1.66	36	31	60	15	18
Debt-free Net Working Capital (DFNWC)	-0.70	77	0.07	-0.34	140	123	168	184	187	179	185
Net Working Capital (NWC)	-1.70	73	-2.63	-3.04	130	123	167	181	183	170	176
Net Nonoperating Expense (NNE)	-0.40	0.13	-0.06	-0.04	0.16	-2.47	-4.95	0.18	-1.82	-4.40	-0.68
Net Nonoperating Obligations (NNO)	0.43	-73	1.04	1.32	-151	-111	-117	-166	-122	-137	-136
Total Depreciation and Amortization (D&A)	0.00	2.56	0.00	0.00	0.00	0.93	0.63	0.64	0.75	0.67	0.67
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-13.46%	0.00%	0.00%	45.21%	-0.81%	18.22%	16.61%	33.55%	8.70%	10.38%
Debt-free Net Working Capital to Revenue	0.00%	39.77%	0.00%	0.00%	2,411.53%	60.06%	84.94%	97.77%	104.95%	103.22%	109.37%
Net Working Capital to Revenue	0.00%	37.95%	0.00%	0.00%	2,233.46%	60.00%	84.18%	96.00%	102.33%	97.98%	104.06%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.04)	$0.29	$0.00	($0.12)	$0.03	$0.57	$0.21	$0.02	$0.12	$0.15	$0.11
Adjusted Weighted Average Basic Shares Outstanding	5.49M	94.19M	5.32M	5.22M	95.10M	96.56M	103.28M	103.51M	102.64M	103.00M	102.58M
Adjusted Diluted Earnings per Share	($0.04)	$0.29	$0.00	($0.12)	$0.03	$0.57	$0.21	$0.02	$0.12	$0.15	$0.11
Adjusted Weighted Average Diluted Shares Outstanding	5.49M	94.19M	5.49M	5.49M	95.10M	96.56M	103.28M	103.51M	102.64M	103.00M	102.58M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.49M	5.22M	5.22M	5.22M	103.02M	103.61M	103.61M	103.88M	102.58M	102.58M	102.85M
Normalized Net Operating Profit after Tax (NOPAT)	14	30	-0.35	-0.35	19	42	17	10	11	9.88	11
Normalized NOPAT Margin	29.65%	20.39%	0.00%	0.00%	35.13%	27.56%	34.94%	23.50%	25.40%	24.98%	24.72%
Pre Tax Income Margin	44.57%	35.05%	0.00%	0.00%	24.69%	39.95%	66.45%	31.23%	42.69%	46.93%	43.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	5,295.07	0.00	0.00	0.00	2,397.62	0.00	5,059.17	273.25	379.05	332.03	164.19
NOPAT to Interest Expense	1,924.95	0.00	0.00	0.00	547.31	0.00	2,664.44	52.82	226.43	176.18	92.73
EBIT Less CapEx to Interest Expense	5,295.07	0.00	0.00	0.00	2,397.62	0.00	5,070.40	295.37	399.30	402.01	163.10
NOPAT Less CapEx to Interest Expense	1,924.95	0.00	0.00	0.00	547.31	0.00	2,675.67	74.94	246.68	246.16	91.64
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-523.69%	9,066.23%	0.00%	0.00%	0.00%	0.00%	0.00%	9.80%	0.00%

Financials Breakdown Chart

SBC Medical Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, SBC Medical Group's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

SBC Medical Group's net income appears to be on an upward trend, with a most recent value of $51.05 million in 2025, rising from $38.56 million in 2023. The previous period was $46.69 million in 2024. See where experts think SBC Medical Group is headed by visiting SBC Medical Group's forecast page.

SBC Medical Group's total operating income in 2025 was $67.49 million, based on the following breakdown:

Total Gross Profit: $127.28 million
Total Operating Expenses: $59.80 million

Over the last 2 years, SBC Medical Group's total revenue changed from $193.54 million in 2023 to $173.61 million in 2025, a change of -10.3%.

SBC Medical Group's total liabilities were at $117.14 million at the end of 2025, a 64.8% increase from 2024, and a 2,451.6% increase since 2022.

In the past 3 years, SBC Medical Group's cash and equivalents has ranged from $485.56 thousand in 2022 to $163.77 million in 2025, and is currently $163.77 million as of their latest financial filing in 2025.

Over the last 2 years, SBC Medical Group's book value per share changed from 25.90 in 2023 to 2.42 in 2025, a change of -90.7%.

Related Companies

Financial statements for NASDAQ:SBC last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SBC Medical Group (SBC) Financials

Financials Breakdown Chart

SBC Medical Group Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SBC Medical Group (SBC) Financials

Annual Income Statements for SBC Medical Group

Quarterly Income Statements for SBC Medical Group

Annual Cash Flow Statements for SBC Medical Group

Quarterly Cash Flow Statements for SBC Medical Group

Annual Balance Sheets for SBC Medical Group

Quarterly Balance Sheets for SBC Medical Group

Annual Metrics And Ratios for SBC Medical Group

Quarterly Metrics And Ratios for SBC Medical Group

Financials Breakdown Chart

SBC Medical Group Financials - Frequently Asked Questions

When does SBC Medical Group's financial year end?

How has SBC Medical Group's net income changed over the last 2 years?

What is SBC Medical Group's operating income?

How has SBC Medical Group's revenue changed over the last 2 years?

How much debt does SBC Medical Group have?

How much cash does SBC Medical Group have?

How has SBC Medical Group's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools